Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate
Source: View publication →
In women with a prior spontaneous preterm birth, weekly administration of 17 alpha-hydroxyprogesterone caproate (17P) significantly reduces the risk of recurrent preterm delivery compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
This trial established 17-hydroxyprogesterone caproate as the standard of care for the prevention of recurrent spontaneous preterm birth in women with a history of prior preterm delivery, significantly impacting obstetric practice and neonatal morbidity reduction for two decades.
Historical Context
Prior to this landmark trial, evidence supporting progesterone therapy for preterm birth prevention was inconsistent and derived from small, disparate studies. The Meis trial provided the first robust, multicenter randomized controlled evidence, which led to widespread clinical adoption and established 17-OHPC as a primary preventive strategy in high-risk pregnancies.
Guided Discussion
High-yield insights from every perspective
What is the biological role of progesterone in maintaining pregnancy, and why was 17-alpha-hydroxyprogesterone caproate (17P) hypothesized to prevent recurrent preterm birth?
Key Response
Progesterone is essential for maintaining uterine quiescence. It inhibits the production of pro-inflammatory cytokines and prostaglandins, decreases the expression of contraction-associated proteins, and modulates the immune response at the maternal-fetal interface. 17P is a synthetic progestogen that mimics these effects to delay the onset of labor in women with a history of spontaneous preterm delivery.
According to the Meis trial, what are the specific criteria for patient selection and the recommended timing for initiating 17P therapy to reduce the risk of recurrent preterm birth?
Key Response
The study included women with a singleton pregnancy and a documented history of a previous spontaneous preterm delivery (defined as delivery between 20 and 36 weeks 6 days). Treatment should be initiated between 16 weeks 0 days and 20 weeks 6 days of gestation and continued weekly until 36 weeks 6 days or delivery.
The Meis trial demonstrated a reduction in delivery at <37, <35, and <32 weeks. How does the magnitude of the effect on neonatal morbidity, specifically rates of intraventricular hemorrhage and necrotizing enterocolitis, inform the clinical value of 17P beyond just prolonging gestation?
Key Response
The trial found significant reductions in several neonatal morbidities: necrotizing enterocolitis was reduced from 2.7% to 0%, and intraventricular hemorrhage from 5.2% to 1.3%. This suggests that 17P does not merely delay birth slightly but significantly improves neonatal survival and quality of life by preventing early-gestation deliveries where these complications are most prevalent.
How do you reconcile the robust positive results of the 2003 Meis trial with the subsequent negative results of the 2019 PROLONG trial when counseling a high-risk patient today?
Key Response
The Meis trial was conducted in a higher-risk population with a 54.9% preterm birth rate in the placebo group, whereas the PROLONG trial (Study 003) had a much lower placebo rate (approx. 11%). This suggests that 17P's efficacy may be most pronounced in very high-risk populations, though the FDA ultimately withdrew approval because the confirmatory trial failed to replicate the clinical benefit in a modern, lower-risk cohort.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The Meis trial utilized a 2:1 randomization scheme (treatment to placebo). What are the specific implications of this allocation ratio regarding the statistical power for secondary outcomes and the potential for detecting rare adverse events?
Key Response
A 2:1 ratio increases the number of participants exposed to the active drug, enhancing the safety profile database and potentially improving recruitment. However, for a fixed total sample size, it reduces the statistical power to detect differences in the primary outcome compared to 1:1 randomization. It also complicates the detection of rare side effects if those effects are similar to baseline pregnancy complications.
As a reviewer, the 54.9% preterm birth rate in the placebo arm of the Meis trial stands out as exceptionally high. To what extent does this 'high-risk' baseline limit the external validity of the study for the general obstetric population in the United States?
Key Response
An unusually high event rate in the control group can lead to an overestimation of treatment effect (Absolute Risk Reduction) when applied to the general population. Editors would flag this as a threat to generalizability, as the study population—largely recruited from academic centers with high rates of poverty and prior PTB—might not represent the standard risk profile seen in community practice.
Given that the Meis trial was the primary evidence for ACOG and SMFM recommendations for nearly two decades, how should committees pivot following the 2023 FDA withdrawal of Makena (17P)?
Key Response
Committees must now emphasize that while the Meis trial was methodologically sound for its time, the failure of the confirmatory PROLONG trial indicates that 17P lacks a consistent clinical benefit across modern populations. Current guidelines (ACOG Practice Advisory) have shifted toward recommending vaginal progesterone for those with a short cervix and de-emphasizing 17P for history-indicated prophylaxis.
Clinical Landscape
Noteworthy Related Trials
PREGVID Trial
Tested
Vaginal progesterone 200mg daily
Population
Asymptomatic women with a short cervix
Comparator
Placebo
Endpoint
Preterm birth before 34 weeks of gestation
OPPTIMUM Study
Tested
Vaginal progesterone 200mg daily
Population
Women at risk of preterm birth
Comparator
Placebo
Endpoint
Composite of perinatal mortality, morbidity, and neurodevelopmental impairment
IMPROVE Study
Tested
Vaginal progesterone 200mg daily
Population
Women with prior preterm birth and singleton gestation
Comparator
Placebo
Endpoint
Preterm birth before 37 weeks
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis